Biofrontera Q1 2024 GAAP EPS $(2.88) Misses $(1.17) Estimate, Sales $7.912M Miss $10.857M Estimate
Portfolio Pulse from Benzinga Newsdesk
Biofrontera (NASDAQ:BFRI) reported Q1 2024 GAAP EPS of $(2.88), missing the $(1.17) estimate by 146.15%. Sales were $7.912M, missing the $10.857M estimate by 27.12%. Despite a 48.57% improvement in EPS from last year, sales decreased by 9.40%.
May 15, 2024 | 9:19 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Biofrontera reported Q1 2024 GAAP EPS of $(2.88), significantly missing the $(1.17) estimate. Sales also missed expectations, coming in at $7.912M versus the $10.857M estimate. Despite an improvement in EPS from last year, sales decreased by 9.40%.
The significant miss on both EPS and sales estimates is likely to negatively impact Biofrontera's stock price in the short term. Although there was an improvement in EPS from last year, the overall financial performance did not meet market expectations.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100